Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong, Jianjun Zhang, Michael Tolstorukov, Yvonne Y. Li, Liam F. Spurr, Andrew D. Cherniack, Gonzalo Recondo, Giuseppe Lamberti, Xinan Wang, Deepti Venkatraman, Joao V. Alessi, Victor R. Vaz, Hira Rizvi, Jacklynn V. Egger, Andrew J. Plodkowski, S. Khosrowjerdi, Subba R. Digumarthy, Hyesun Park, Nuno Vaz, Mizuki Nishino, Lynette M. Sholl, David A. Barbie, Mehmet Altan, John V. Heymach, Ferdinandos Skoulidis, Justin F. Gainor, Matthew D. Hellmann, Mark M. Awad
Topics & Concepts
STK11MedicineMutantAdenocarcinomaKRASCancer researchMutationLungOncologyInternal medicineGeneticsCancerBiologyGeneColorectal cancerCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsMelanoma and MAPK Pathways